Syros Pharmaceuticals, Inc. (SYRS) Financials

SYRS Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2024 85.0 million 96.1 million
June 30, 2024 106.7 million 113.1 million
March 31, 2024 134.7 million 119.7 million
Dec. 31, 2023 168.2 million 151.5 million

SYRS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2024 -20.7 million 1.6 million
June 30, 2024 -29.7 million 1.8 million
March 31, 2024 -31.1 million 2.1 million
Dec. 31, 2023 -18.6 million 1.7 million

SYRS Net Income

No data available :(

SYRS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2024 58.3 million 16.6 million 19.1 million
June 30, 2024 79.0 million 40.9 million 17.2 million
March 31, 2024 108.3 million 29.7 million 17.9 million
Dec. 31, 2023 139.5 million 34.6 million 18.5 million

SYRS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2024 39.3 million
June 30, 2024 39.3 million
March 31, 2024 39.0 million
Dec. 31, 2023 29.5 million

SYRS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2024 - 20.5 million 5.7 million -
June 30, 2024 - 21.6 million 5.5 million -
March 31, 2024 - 24.3 million 6.3 million -
Dec. 31, 2023 38000 21.2 million 5.9 million -

SYRS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2024 - 325000
June 30, 2024 - 331000
March 31, 2024 - 334000
Dec. 31, 2023 386000 279000

SYRS

Price: $0

52 week price:
0.00
0.04

Earnings Per Share: -3.07 USD

P/E Ratio: -0.01

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 234220

Ebitda: -13.6 million

Market Capitalization: 5366

Links: